- Conditions
- Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
- Interventions
- transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 14 Years to 30 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postmenopause
- Interventions
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 662 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 17
- States / cities
- Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more